Invuity, Inc. (IVTY) on Focus After Trading At All-Time Lows

February 15, 2018 - By Adrian Erickson

The stock of Invuity, Inc. (NASDAQ:IVTY) reached all time low today, Feb, 15 and still has $3.52 target or 5.00 % below today’s $3.70 share price. This indicates more downside for the $63.56 million company. This technical setup was reported by Barchart.com. If the $3.52 PT is reached, the company will be worth $3.18M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only.

The stock decreased 3.90% or $0.15 during the last trading session, reaching $3.7. About 158,915 shares traded. Invuity, Inc. (NASDAQ:IVTY) has risen 50.92% since February 15, 2017 and is uptrending. It has outperformed by 34.22% the S&P500.

Invuity, Inc. (NASDAQ:IVTY) Ratings Coverage

Among 4 analysts covering Invuity Inc (NASDAQ:IVTY), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Invuity Inc had 7 analyst reports since August 29, 2016 according to SRatingsIntel. Lake Street initiated the shares of IVTY in report on Monday, September 19 with “Buy” rating. The stock has “Buy” rating by Piper Jaffray on Tuesday, July 25. Northland Capital maintained Invuity, Inc. (NASDAQ:IVTY) on Wednesday, July 26 with “Buy” rating. The firm earned “Buy” rating on Tuesday, June 13 by Northland Capital. The firm has “Buy” rating by Craig Hallum given on Monday, August 29.

More news for Invuity, Inc. (NASDAQ:IVTY) were recently published by: Digitaljournal.com, which released: “Invuity Inc. to Host Earnings Call” on February 13, 2018. Globenewswire.com‘s article titled: “Invuity Announces Fourth Quarter and Full Year 2017 Financial Results” and published on February 13, 2018 is yet another important article.

Invuity, Inc., a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company has market cap of $63.56 million. The firm integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges. It currently has negative earnings. It offers various illuminated surgical devices, including Eikon LT Illuminated and Eikon illuminated retractor systems for breast oncology/oncoplastic/general/orthopedics surgeries; Saber Yankauer, a handheld illuminator for orthopedic/spine/cardiothoracic/breast/general surgeries; and Saber Frazier, a handheld illuminator for spine/orthopedic/neurosurgery surgeries.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.